Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy


Perol M., Ciuleanu T., ARRİETA O., Prabhash K., Syrigos K. N. , GÖKSEL T. , ...Daha Fazla

LUNG CANCER, cilt.93, ss.95-103, 2016 (SCI İndekslerine Giren Dergi) identifier identifier identifier

Özet

Objectives: REVEL demonstrated that ramucirumab + docetaxel (RAM + DTX) improved overall survival, progression-free survival, and objective response rate in patients with advanced/metastatic non-small cell lung cancer with progression after platinum-based chemotherapy. This analysis examined quality of life (QoL) as assessed by the Lung Cancer Symptom Scale (LCSS) and clinician-reported functional status.